Michung Yoon

Prof. Dr. Michung Yoon

Department of Biomedical Engineering, Mokwon University, Daejeon, South Korea

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2009 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
SJSunhyo Jeong
Sunhyo Jeong
Michung YoonMichung Yoon
Michung Yoon
Experimental & Molecular Medicine is an open access journal that publishes the highest quality articles in translational research and biomedical studies.

4 February 2011 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
SJSunhyo Jeong
Sunhyo Jeong
Michung YoonMichung Yoon
Michung Yoon

1 January 2010 in PPAR Research
Verified
Journal Article
Open access
PDF file
Michung YoonMichung Yoon
Michung Yoon
Peroxisome proliferator-activated receptorα(PPARα) is a member of the steroid hormone receptor superfamily and is well known to act as the molecular target for lipid-lowering drugs of the fibrate family. At the molecular level, PPARαregulates the transcription of a number of genes critical for lipid and lipoprotein metabolism. PPARαactivators are further shown to reduce body weight gain and adiposity, at least in part, due to the increase of hepatic fatty acid oxidation and the decrease in levels of circulating triglycerides responsible for adipose cell hypertrophy and hyperplasia. However, these effects of the PPARαligand fenofibrate on obesity are regulated with sexual dimorphism and seem to be influenced by the presence of functioning ovaries, suggesting the involvement of ovarian steroids in the control of obesity by PPARα. In female ovariectomized mice, 17β-estradiol inhibits the actions of fenofibrate on obesity through its suppressive effects on the expression of PPARαtarget genes, and these processes may be mediated by inhibiting the coactivator recruitment of PPARα. Thus, it is likely that PPARαfunctions on obesity may be enhanced in estrogen-deficient states.

3 October 2018 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
HLHyunghee Lee
Hyunghee Lee
JAJiwon Ahn
Jiwon Ahn
SSSoon Shik Shin
Soon Shik Shin
Michung YoonMichung Yoon
Michung Yoon

23 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BPByung Young Park
Byung Young Park
HLHyunghee Lee
Hyunghee Lee
SWSangee Woo
Sangee Woo
MYMiso Yoon
Miso Yoon
JKJeongjun Kim
Jeongjun Kim
Michung YoonMichung Yoon
Michung Yoon
It has been suggested that angiogenesis modulates adipogenesis and obesity. This study was undertaken to determine whether ALS-L1023 (ALS) prepared by a two-step organic solvent fractionation from Melissa leaves, which exhibits antiangiogenic activity, can regulate adipose tissue growth. The effects of ALS on angiogenesis and extracellular matrix remodeling were measured using in vitro assays. The effects of ALS on adipose tissue growth were investigated in high fat diet-induced obese mice. ALS inhibited VEGF- and bFGF-induced endothelial cell proliferation and suppressed matrix metalloproteinase (MMP) activity in vitro. Compared to obese control mice, administration of ALS to obese mice reduced body weight gain, adipose tissue mass and adipocyte size without affecting appetite. ALS treatment decreased blood vessel density and MMP activity in adipose tissues. ALS reduced the mRNA levels of angiogenic factors (VEGF-A and FGF-2) and MMPs (MMP-2 and MMP-9), whereas ALS increased the mRNA levels of angiogenic inhibitors (TSP-1, TIMP-1, and TIMP-2) in adipose tissues. The protein levels of VEGF, MMP-2 and MMP-9 were also decreased by ALS in adipose tissue. Metabolic changes in plasma lipids, liver triglycerides, and hepatic expression of fatty acid oxidation genes occurred during ALS-induced weight loss. These results suggest that ALS, which has antiangiogenic and MMP inhibitory activities, reduces adipose tissue mass in nutritionally obese mice, demonstrating that adipose tissue growth can be regulated by angiogenesis inhibitors.